SEPSIA THERAPEUTICS
LIVE

Serial Number

79364021

Owner

SEPSIA THERAPEUTICS, S.L.

Attorney

Elizabeth Lee D'Amore

Filing Date

Oct 26, 2022

Add to watchlist:

No watchlists yet
View on USPTO

SEPSIA THERAPEUTICS Trademark

Serial Number: 79364021 • Registration: 7567463

SEPSIA THERAPEUTICS is a trademark filed by SEPSIA THERAPEUTICS, S.L. on October 26, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

SEPSIA THERAPEUTICS, S.L.

Torre Inbisa. Plaza Europa, 9-11, planta 13,

Entity Type: 99

Trademark Details

Filing Date

October 26, 2022

Registration Date

November 19, 2024

Published for Opposition

September 3, 2024

Goods & Services

Scientific and technological services, as well as associated research and design services, namely, scientific research and development in the fields of biochemicals, pharmacy, medicine and veterinary medicine; industrial analysis services related to biology, biochemistry, chemistry, pharmacy, medicine and veterinary medicine, industrial research in the fields of biology, biochemistry, chemistry, pharmacy, medicine and veterinary medicine; scientific research services related to biology, biochemistry, chemistry, pharmacy, medicine and veterinary medicine; scientific research services related to the treatment of infectious diseases and related inflammatory processes, sepsis and advanced cell therapies and immunotherapy; scientific research services related to peptides and proteins for pharmaceutical, medical and veterinary use

Medical machines for dialysis, hemoperfusion and hemoadsorption; medical devices for blood purification, namely, hemoperfusion machines; medical adsorption devices and polymeric adsorption materials for the removal of materials from the blood or from blood fractions and kits primarily containing said testing devices for the identification of bacteria for medical use; electrical instruments for medical use in blood diagnostic analysis; assay instruments for medical diagnostic use in measuring, testing and analyzing blood, body fluids, cells, proteins, peptides and nucleic acids for infectious diseases and associated inflammatory processes, sepsis and in advanced cell therapies and immunotherapy; medical diagnostic testing instruments for use in immunoassay procedures; diagnostic apparatus for medical use in measuring, testing and analyzing blood, body fluids, cells, proteins, peptides and nucleic acids for infectious diseases and associated inflammatory processes, sepsis and in advanced cell therapies and immunotherapy; medical diagnostic testing apparatus for use in measuring, testing and analyzing blood, body fluids, cells, proteins, peptides and nucleic acids for immunoassay procedures; apparatus and instruments for diagnostic testing for medical purposes in measuring, testing and analyzing blood, body fluids, cells, proteins, peptides and nucleic acids for infectious diseases and associated inflammatory processes, sepsis and in advanced cell therapies and immunotherapy; apparatus and instruments for veterinary diagnosis in measuring, testing and analyzing blood, body fluids, cells, proteins, peptides and nucleic acids for infectious diseases and associated inflammatory processes, sepsis and in advanced cell therapies and immunotherapy; medical diagnostic instruments for diagnosis in measuring, testing and analyzing blood, body fluids, cells, proteins, peptides and nucleic acids for infectious diseases and associated inflammatory processes, sepsis and in advanced cell therapies and immunotherapy; dialysis apparatus, namely, dialysis and hemofiltration machines; dialysis machines for veterinary use, namely, dialysis and hemofiltration machines; dialysis machines for medical use

Pharmaceutical products namely, pharmaceutical preparations for human and veterinary use for the treatment of infectious diseases, inflammatory conditions, sepsis, advanced cell therapies and immunotherapy; biological preparations for medical and veterinary use, namely, biological preparations for the treatment of infectious diseases; pharmaceutical, biological and veterinary preparations for the treatment of infectious diseases and related inflammatory processes, for the treatment of sepsis and for advanced cell therapies and immunotherapy; pharmaceutical preparations containing nucleic acids and proteins and active peptides for medical and veterinary use, namely, pharmaceutical preparations containing nucleic acids and proteins and active peptides for the treatment of infectious diseases and related inflammatory processes, for the treatment of sepsis and for advanced cell therapies and immunotherapy

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 4, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Dec 4, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 4, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 4, 2025 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
May 3, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 14, 2025 FICS
FINAL DISPOSITION PROCESSED
Apr 14, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 19, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 19, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 19, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 3, 2024 NPUB
PUBLISHED FOR OPPOSITION
Sep 3, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Aug 17, 2024 OPNX
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 14, 2024 NONP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 31, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jul 31, 2024 OPNR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 25, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 25, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 25, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 25, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 25, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 24, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 24, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 24, 2024 TROA
REFUSAL PROCESSED BY IB
Mar 26, 2024 RFNT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 25, 2024 GNRN
NON-FINAL ACTION E-MAILED
Feb 25, 2024 GNRT
NON-FINAL ACTION WRITTEN
Feb 25, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 25, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 24, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 24, 2024 TROA
REFUSAL PROCESSED BY IB
Oct 4, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 11, 2023 RFCS
REFUSAL PROCESSED BY MPU
Sep 11, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 19, 2023 RFCR
NON-FINAL ACTION WRITTEN
Aug 18, 2023 CNRT
ASSIGNED TO EXAMINER
Aug 10, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 7, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 3, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 2, 2023 REPR